Convenient daily medical robotics news feed from outside sources
Be a part of our "Spotlight Feature"
If you are a Robotic Surgeon, Medical Robotics Scientist, or in any other way professionally involved with Medical Robotics and you would like to find out more about how to become our next "Spotlight Feature", please feel free to contact us at: email@example.com
• Please include your name, title, profession and/or specialty and possibly a link to your website.
Is the number one genetic killer of children under the age of two, is an often fatal disease that destroys the nerves controlling voluntary muscle movement, which affects crawling, walking, head and neck control, and even swallowing.
WHO IS AFFECTED
SMA is one of the most prevalent genetic disorders.
One in every 6,000 babies is born with SMA.
SMA can strike anyone of any age, race or gender.
One in every 40 people carries the gene that causes SMA. The child of two carriers has a one in four chance of developing SMA.
7.5 million Americans are carriers.
THE TYPES OF SMA
SMA Patients are classified into four types based on milestones achieved at onset of SMA. Type I and II are the most prevalent.
Type I, or Werdnig-Hoffmann Disease, is the most severe form of SMA. Type I SMA strikes infants between birth and six months old. Children affected with Type I cannot sit without support.
Type II affects infants between seven and 18 months old. Type II patients may be able to sit unaided or even stand with support. They are at increased risk for complications from respiratory infections.
Type III, also known as Kugelberg-Welander Disease, is the least deadly form of childhood-onset SMA. It strikes children as early as the age of 18 months, but can surface as late as adolescence. Type III patients are able to walk, but weakness is prevalent. Most patients eventually need to use a wheelchair.
Type IV is the adult form of the disease. Symptoms tend to begin after age 35.
SMA does not affect sensation and intellectual activity in patients. It commonly is observed that patients with SMA are unusually bright and sociable.
Families of SMA
funds and directs the leading SMA research programs to develop a treatment and cure for the disease. The successful results and progress that the organization has delivered, from basic research to drug discovery to clinical trials, provide real hope for families and patients impacted by the disease. The charity has invested over $55 million in research and has been involved in funding almost two thirds of all the ongoing novel drug programs for SMA.
Any medical information published on this website is intended purely as a informational tool only and is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional.
The Copyright of all images and documents is by the According Developing Group, Institute, Editor or Company. We only included data and images freely accessible. We have linked each image and/or story back to it's original source. If you want your system or certain information on it removed from our website, please contact us at firstname.lastname@example.org